This is the authors' abstract. We don't add key points for this paper.
Lung ischemia–reperfusion injury (LIRI) contributes to early graft dysfunction after lung transplantation, yet effective pharmacological interventions remain limited. Calycosin (CA), an isoflavone sourced from Astragali Radix, has shown protective effects in experimental ischemic injury, but its effects on LIRI remain insufficiently characterized. We integrated network analysis and molecular docking with experiments in human umbilical vein endothelial cells subjected to oxygen–glucose deprivation/reoxygenation (OGD/R) and male Sprague–Dawley rats undergoing left pulmonary hilar occlusion and reperfusion. Computational analyses highlighted inflammatory signaling, redox regulation, and cell survival, with CA improving endothelial viability and reducing oxidative stress, apoptosis, and inflammatory cytokine levels. In rats, CA reduced histological injury, edema, inflammatory cell accumulation, and lipid peroxidation while improving arterial oxygenation, superoxide dismutase activity, and tissue ATP content. Protection was accompanied by changes in candidate gene expression and PPARγ, COX-2, BAX, and BCL2 protein abundance. In endothelial cells, the PPARγ antagonist GW9662 attenuated the protective effects of CA and its reduction of NF-κB p65 nuclear accumulation. These findings support CA’s potential as a candidate intervention for LIRI and identify PPARγ as a contributor to its endothelial–protective effects, providing a rationale for further evaluation in lung preservation and transplantation models.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Heng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: